Free tool
FAERS Monitor: Dilantin-125
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 008762 or its brand name (Dilantin-125, Phenytoin). Reports on generic versions are filed under their own applications.
Reports
20,902
Serious
18,748
90% of reports
Hospitalization
8,547
Death reported
2,991
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective2,771
- drug interaction1,580
- seizure1,426
- toxicity to various agents1,372
- convulsion1,260
- off label use1,140
- status epilepticus812
- stevens-johnson syndrome771
- pyrexia686
- fall618
- dizziness606
- drug reaction with eosinophilia and systemic symptoms603
- condition aggravated584
- somnolence553
- epilepsy546
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 569 |
| 2005 | 621 |
| 2006 | 433 |
| 2007 | 499 |
| 2008 | 682 |
| 2009 | 659 |
| 2010 | 895 |
| 2011 | 1,213 |
| 2012 | 1,038 |
| 2013 | 1,000 |
| 2014 | 907 |
| 2015 | 989 |
| 2016 | 929 |
| 2017 | 1,102 |
| 2018 | 1,201 |
| 2019 | 1,250 |
| 2020 | 1,232 |
| 2021 | 1,121 |
| 2022 | 1,114 |
| 2023 | 1,131 |
| 2024 | 988 |
| 2025 | 867 |
| 2026 | 462 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,033,257 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| status epilepticusSignal | 812 | 77.9 | 72.6 | 57,167 |
| stevens-johnson syndromeSignal | 771 | 36.1 | 33.6 | 25,391 |
| drug reaction with eosinophilia and systemic symptomsSignal | 603 | 24.1 | 22.3 | 13,046 |
| convulsionSignal | 1,260 | 22.6 | 21.5 | 25,547 |
| epilepsySignal | 546 | 18.3 | 16.8 | 8,755 |
| seizureSignal | 1,426 | 12.6 | 11.9 | 15,064 |
| drug interactionSignal | 1,580 | 10.1 | 9.6 | 12,933 |
| toxicity to various agentsSignal | 1,372 | 8.2 | 7.8 | 8,727 |
| somnolenceSignal | 553 | 2.8 | 2.5 | 627 |
| drug ineffectiveSignal | 2,771 | 2.1 | 2.0 | 1,740 |
| pyrexia | 686 | 2.0 | 1.9 | 345 |
| condition aggravated | 584 | 1.9 | 1.8 | 266 |
| fall | 618 | 1.9 | 1.7 | 253 |
| off label use | 1,140 | 1.3 | 1.2 | 87 |
| dizziness | 606 | 1.2 | 1.1 | 25 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.